



## Ceva completes acquisition of IDT veterinary business assets, moving closer to its 2020 objective of 50:50 bio-pharma split

Libourne & Dessau 3<sup>rd</sup> July 2019 - Ceva Santé Animale (“Ceva”) and IDT Biologika GmbH (“IDT”) today announced that they have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva.

The product portfolio will be transferred to Ceva branding as quickly as possible. A new Global innovation center focused on swine vaccines will be created within IDT’s exiting Dessau site.



*IDT BioPharmaPark site in Dessau-Rosslau (Germany)*

Ceva has rapidly moved from a 33:67 bio-pharma split in 2014 to 45:55 in 2018. With addition of the IDT vaccine range and rapid growth of its own new technology vaccines, the split will be close to the 50:50 balance originally set out in its “Ambition 2020” business plan. Coupled together with the complimentary tools of autogenous vaccines and improved diagnostics this shift underlines Ceva’s belief that preventative medicine is the key to future health.

IDT’s strong range of swine vaccines will strengthen Ceva’s rapidly growing presence in this segment. The deal will also boost Ceva’s Veterinary Public Health offer in both food safety, with **Salmovac 440**, a salmonella vaccine for chickens and in rabies control, with **Rabitec**, an innovative, latest generation rabies vaccine for the oral immunisation of foxes and other species, which will play a crucial role in campaigns focused on the successful eradication of rabies worldwide.

IDT is set to focus on the production of human vaccines and medicines going forward. Business in contract manufacturing and development of human medicines has seen dynamic growth over the past few years, making it contribute as much as two thirds of its total turnover.

**Dr. Marc Prikazsky, Chairman & CEO of Ceva said:** “Both Ceva and IDT have been driven by a deep desire to quickly develop effective vaccine solutions for our customers. It marks the 100-year heritage we share and this coupled with a similar entrepreneurial mindset, is what will ensure the success of the new business in the future.”

**Carsten Klocke, CEO of Klocke Holding, added:** *“We’re content to see our animal health business transfer into Ceva, an organization providing the optimal environment for its continued positive development. This successful transaction now allows IDT to focus on building a leading global position in biotechnological human vaccines and medicine, a market with huge growth potential mid- and long-term.”*

Click [here](#) to download copyright-free photos

- ends -

---

#### **About Ceva Santé Animale:**

Ceva Santé Animale is a French multinational veterinary pharmaceutical company created in 1999. Chaired by Dr. Marc Prikazsky, Ceva specializes in the research, development, production and marketing of pharmaceutical products and vaccines for livestock (ruminants, swine, poultry) and companion animals.

Ceva is present in 110 countries and employs over 5700 people worldwide. Since 2007, its management and employees have been the majority shareholders in Ceva Santé Animale, which Chairman and CEO is Dr. Marc Prikazsky.

Websites: <http://www.ceva.com>



#### **PRESS CONTACT**

Martin Mitchell - Communication Director +33 05 57 55 40 80  
[martin.mitchell@ceva.com](mailto:martin.mitchell@ceva.com)

#### **About IDT Biologika**

IDT Biologika is an innovative, privately-held company with nearly 100 years of experience in researching, developing, manufacturing and marketing products for the global protection of human and animal health. The company produces vaccines and pharmaceuticals according to the highest quality standards, for its own animal health products and under contract.

Company sites in Germany include the BioPharmaPark in Dessau-Rosslau and the Riems district of Greifswald. IDT's Animal Health business is marketed internationally from its offices in Denmark, the Netherlands, France, Spain, Poland and Canada. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland. In Canada, IDT Biologika subsidiary Gallant Custom Laboratories manufactures autogenous vaccines. The same vaccines are produced by the recently acquired IDT subsidiary in the United Kingdom, Ridgeway Biologicals.

IDT Biologika is a member of the Klocke Group, which is specialized in contract production and packaging of medications, vaccines and cosmetic products. As a traditional family-owned company, the Klocke Group employs a workforce of more than 2,500 people at nine production sites and sales offices around the world. For more information, visit [www.idt-biologika.com](http://www.idt-biologika.com).

#### **PRESS CONTACT**

Christian Herschel - External Corporate Communications +49 34901 885 4293  
[Christian.Herschel@idt-biologika.de](mailto:Christian.Herschel@idt-biologika.de) / [Pressestelle@idt-biologika.de](mailto:Pressestelle@idt-biologika.de)